Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Sales and Divestitures (2022 - 2025)

Lyra Therapeutics (LYRA) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $34182.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 22.65% to $34182.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $34182.0, a 22.65% increase, with the full-year FY2024 number at $86574.0, up 1129.57% from a year prior.
  • Gains from Sales and Divestitures was $34182.0 for Q3 2025 at Lyra Therapeutics, up from $15104.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $365121.0 in Q1 2025 to a low of $1302.0 in Q2 2022.
  • A 4-year average of $55113.2 and a median of $15104.0 in 2025 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 1722.65% in 2024, then plummeted 45.8% in 2025.
  • Lyra Therapeutics' Gains from Sales and Divestitures stood at $1953.0 in 2022, then soared by 260.52% to $7041.0 in 2023, then soared by 1129.57% to $86574.0 in 2024, then plummeted by 60.52% to $34182.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Gains from Sales and Divestitures are $34182.0 (Q3 2025), $15104.0 (Q2 2025), and $365121.0 (Q1 2025).